What we do Laurus Labs is a science-led pharmaceutical and biotechnology company specializing in APIs, finished dosage forms, synthesis, and specialty ingredients, serving global markets with a focus on anti-retrovirals, oncology, and other therapies. |
Founded in 2,005 |
Market share A leading supplier of generic APIs in ARV and oncology with global regulatory approvals and expanding contract development and manufacturing capabilities. |
Problem solved Addresses the need for affordable high-quality generic pharmaceuticals and advanced manufacturing services for global healthcare markets. |
Top clients or who we serve Serves multinational pharmaceutical companies including Aspen Pharmacare, Aurobindo Pharma, Cipla, Mylan, Natco; targeting global B2B pharmaceutical formulation and healthcare sectors. |
Key management Dr. Satyanarayana Chava (CEO) and V.V. Ravi Kumar (CFO) lead the company, supported by an experienced board including Dr. K. Ravindranath as Chairman. |
Our journey and innovations Since inception in 2005, Laurus expanded from APIs to complex biotech and CDMO services, launching 59 products and pioneering CAR-T therapy manufacturing. |
Where we operate Operations span India, USA, Europe, South Africa, and emerging markets in Sub-Saharan Africa, South-East Asia, and Latin America. |
Top products or what we offer Active pharmaceutical ingredients (APIs), finished dosage forms (FDFs), contract development and manufacturing (CDMO), and specialty ingredients in nutraceuticals and cosmetics. |
Top brands Key offerings include ARV drugs, oncology APIs, and NexCAR19, India's pioneering CAR-T cell therapy; notable for quality, innovation, and regulatory approvals. |
Raw materials needed Specialized chemical intermediates, biotech raw materials, and raw substances for pharmaceutical synthesis and formulation. |
Raw materials supplier Suppliers include global and regional chemical manufacturers and biotechnology providers supporting pharma-grade quality. |
Recurring vs cyclical contribution Revenue stems from a balanced mix of recurring generic drug sales and cyclical contract manufacturing projects with long-term partnerships. |
Our industry position Among top generic API manufacturers with distinct expertise in ARVs and oncology, strong global regulatory certifications, and growing biotech capabilities. |
Financial highlights FY25 revenue of ₹5,554 crore with 10% growth; net profit ₹358 crore, showing strong margin expansion and operational growth. |
Geographical revenue split Approximately 68% revenue from outside India and 32% from within India, reflecting broad global market presence. |
Order book Robust order book driven by strong CDMO pipelines and expanded generics capacities with multiple long-term global contracts. |
Whats driving growth Growth fueled by expanding CDMO capabilities, new product launches, capacity expansions, and increasing demand in ARV, oncology, and biotech segments. |
Our future plans Capex of ₹3,900 crore through 2026 for facility expansions, biotech manufacturing, specialty chemicals, and renewable energy integration. |
Our green promise Commitment to sustainability via ISO 50001, renewable energy projects, and initiatives to improve ESG scores and operational efficiency. |
Our people and values Employs over 7,000 people with focus on R&D excellence, diversity, inclusion, and maintaining Great Place to Work status for four consecutive years. |
Key challenges ahead Regulatory hurdles, competitive pricing pressures, and integration risks from rapid expansion into novel modalities and global markets. |
Interesting facts Launched India’s first CAR-T cell therapy NexCAR19; owns over 34 patents with 152 pending applications worldwide. |
Risks and strategy Mitigates market, regulatory, and operational risks via diversified product portfolio, strong compliance, and continuous R&D investment. |
